Amgen/Allergan’s rituximab biosimilar could be $4bn blockbuster

Amgen/Allergan’s rituximab biosimilar could be $4bn blockbuster

Source: 
Pharmaforum
snippet: 

Ten drugs filed with regulators have potential to become billion-sellers by 2025 according to new research, with a near-copy of Roche’s rituximab from Amgen and Allergan showing the most potential.